| 1 |
Badawy RA, Strigaro G, Cantello R : TMS, cortical excitability and epilepsy: the clinical impact. Epilepsy Res 108 : 153-161, 2014
DOI
|
| 2 |
D'Amico RS, Englander ZK, Canoll P, Bruce JN : Extent of resection in glioma-a review of the cutting edge. World Neurosurg 103 : 538-549, 2017
DOI
|
| 3 |
Davies AM, Weinberg U, Palti Y : Tumor treating fields: a new frontier in cancer therapy. Ann N Y Acad Sci 1291 : 86-95, 2013
DOI
|
| 4 |
Hervey-Jumper SL, Berger MS : Evidence for improving outcome through extent of resection. Neurosurg Clin N Am 30 : 85-93, 2019
DOI
|
| 5 |
Hervey-Jumper SL, Berger MS : Maximizing safe resection of low- and high-grade glioma. J Neurooncol 130 : 269-282, 2016
DOI
|
| 6 |
Kanner AA, Wong ET, Villano JL, Ram Z; EF-11 Investigators : Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100ATM system versus best physician's choice chemotherapy. Semin Oncol 41(Suppl 6) : S25-S34, 2014
DOI
|
| 7 |
Kusne Y, Sanai N : The SVZ and its relationship to stem cell based neuro-oncogenesis. Adv Exp Med Biol 853 : 23-32, 2015
DOI
|
| 8 |
Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, et al. : Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature 560 : 243-247, 2018
DOI
|
| 9 |
Sanai N, Alvarez-Buylla A, Berger MS : Neural stem cells and the origin of gliomas. N Engl J Med 353 : 811-822, 2005
DOI
|
| 10 |
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005
DOI
|
| 11 |
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. : Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318 : 2306-2316, 2017
DOI
|
| 12 |
Venkatesh H, Monje M : Neuronal activity in ontogeny and oncology. Trends Cancer 3 : 89-112, 2017
DOI
|
| 13 |
Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. : NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48 : 2192-2202, 2012.
DOI
|
| 14 |
Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. : Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314 : 2535-2543, 2015
DOI
|
| 15 |
Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, et al. : Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev 23 : 1985-1996, 2014
DOI
|
| 16 |
Toda H, Hamani C, Fawcett AP, Hutchison WD, Lozano AM : The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation. J Neurosurg 108 : 132-138, 2008
DOI
|
| 17 |
Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, et al. : Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature 573 : 532-538, 2019
DOI
|
| 18 |
Venkatesh HS, Johung TB, Caretti V, Noll A, Tang Y, Nagaraja S, et al. : Neuronal activity promotes glioma growth through neuroligin-3 secretion. Cell 161 : 803-816, 2015
DOI
|
| 19 |
Venkatesh HS, Tam LT, Woo PJ, Lennon J, Nagaraja S, Gillespie SM, et al. : Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature 549 : 533-537, 2017
DOI
|
| 20 |
Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M, et al. : Electrical and synaptic integration of glioma into neural circuits. Nature 573 : 539-545, 2019
DOI
|
| 21 |
Zeng Q, Michael IP, Zhang P, Saghafinia S, Knott G, Jiao W, et al. : Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature 573 : 526-531, 2019
DOI
|
| 22 |
Zhang C, Du J, Xu W, Huang H, Gao L : The value of tumor treating fields in glioblastoma. J Korean Neurosurg Soc 63 : 681-688, 2020
DOI
|
webmaster
